SecBot SecBot
Biotech Drug Report Generated Nov 3, 2026

NBI-567

NBIX·NEUROCRINE BIOSCIENCES INC
NEUTRAL
Drug Impact Rating2/10
Trial phase
Phase 2a
Time to market
If successful through Phase 2 and Phase 3, potential approval would be several years away, likely no earlier than 2030-2032 given the Phase 2a trial's estimated completion in mid-2028.
Why 2/10
No hard, dated binary catalyst is scheduled within the next ~12 months. The Phase 2a trial (NCT07832383) was initiated in October 2026 with primary completion estimated around May 2028, more than 18 months away. NBI-567 is an early-stage program at a large, diversified, profitable biotech with multiple approved products, so even a positive or negative readout would have a modest impact on NBIX's share price relative to its commercial revenue and later-stage pipeline.
Actionable Insight NEUTRAL

NBI-567 is an early-stage (Phase 2a) program with no binary catalyst for at least 18 months. The next meaningful event is the Phase 2a readout, estimated around May 2028. For NBIX investors, the more important near-term pipeline catalyst is direclidine (NBI-1117568) in Phase 3 for schizophrenia. NBI-567 is a small, early program within a large, profitable commercial-stage biotech.

Price Chart

Loading chart...

Executive Summary

NBI-567 (NBI-1117567) is an investigational oral drug that activates M1 and M4 muscarinic receptors in the brain, being developed by Neurocrine Biosciences (NBIX) as an add-on treatment for cognitive impairment in mild to moderate Alzheimer's disease. Neurocrine initiated a Phase 2a trial in October 2026 (NCT07832383) enrolling about 135 patients, with primary completion estimated around May 2028. The drug was licensed from Nxera Pharma under a 2021 collaboration, and FDA IND acceptance triggered a $10 million milestone payment. NBI-567 is an early-stage program within Neurocrine's much larger pipeline; the company is a profitable, commercial-stage biotech with over $1.1 billion in quarterly revenue from approved products INGREZZA, CRENESSITY, and VYKAT XR. With no binary catalyst expected for at least 18 months, NBI-567 is a small, distant pipeline contributor for NBIX investors.

How It Works

NBI-567 is an oral pill that activates specific muscarinic receptors (M1 and M4) in the brain. These receptors are like switches that help brain cells communicate, particularly in areas involved in learning and memory. In Alzheimer's disease, these communication pathways break down. Rather than boosting acetylcholine levels broadly (as current Alzheimer's drugs do), NBI-567 directly turns on the M1 and M4 receptors, aiming to improve cognitive function with fewer side effects.

Trial Status

Phase 2a trial (NCT07832383) was initiated in October 2026. The randomized, double-blind, placebo-controlled study will enroll approximately 135 adults aged 50-85 with mild to moderate Alzheimer's disease who are on stable acetylcholinesterase inhibitor therapy. The 12-week treatment period evaluates cognitive performance using a neuropsychological test battery. Primary completion is estimated around May 2028. A Phase 1 study in healthy adults was previously completed.

The Two-Sided Case

▲ Bull Case4
NBI-567 targets the M1 muscarinic receptor, which is directly involved in learning and memory circuits, offering a mechanism of action distinct from acetylcholinesterase inhibitors currently used for Alzheimer's.
The muscarinic agonist class has been clinically validated by KarXT (xanomeline-trospium), which was FDA-approved for schizophrenia in 2024, demonstrating that M1/M4 agonism can be therapeutically useful with manageable side effects.
Neurocrine has deep expertise in CNS drug development and a strong commercial infrastructure (INGREZZA, CRENESSITY, VYKAT XR) that could support a future Alzheimer's launch if the drug succeeds.
The IND acceptance from FDA and initiation of Phase 2 demonstrates the drug cleared early safety hurdles in Phase 1.
▼ Bear Case4
Alzheimer's disease has a high historical failure rate for novel mechanisms in Phase 2, and muscarinic agonists have previously struggled with tolerability (e.g., xanomeline's cholinergic side effects).
The Phase 2a trial is small (135 patients) and only 12 weeks long, which may not be sufficient to demonstrate a convincing cognitive signal.
NBI-567 is one of several muscarinic assets in Neurocrine's pipeline (alongside direclidine in Phase 3 and NBI-1117570 in Phase 2), so it may not receive priority resources if other programs show stronger data.
Primary completion is not expected until May 2028, meaning years of development and capital expenditure before any potential commercial launch.

Upcoming Catalysts

  • Phase 2a topline data readout estimated around May 2028 (primary completion date)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NEUROCRINE BIOSCIENCES INC 8-K NBIX ·Originating report

Sources · 10

Hover a chip for the title
1 prnewswire.com2 varese-group.com3 psychiatrictimes.com4 mugglehead.com5 biospace.com6 pharmacally.com7 clinicaltrials.gov8 prnewswire.com9 stockanalysis.com10 sec.gov